PURPOSE: To report prostate-specific antigen (PSA) relapse-free survival and treatment-related toxicity outcomes after combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) for patients with clinically localized prostate cancer. METHODS AND MATERIALS: Between 1998 and 2009, 229 patients were treated with HDR brachytherapy followed 3 weeks later by supplemental EBRT. The HDR brachytherapy boost consisted of three fractions of 192 Ir (5.5e7.5 Gy per fraction), and EBRT consisted of intensitymodulated radiotherapy delivering an additional 45.0e50.4 Gy directed to the prostate gland and seminal vesicles. Median follow-up was 61 months. RESULTS: Seven-year PSA relapse-free survival for low-, intermediate-, and high-risk patients were 95%, 90%, and 57%, respectively ( p!0.001). Among high-risk patients treated with biological equivalent doses in excess of 190 Gy, 7-year PSA relapse-free survival was 81%. In multivariate analysis, Gleason scores of $8 predicted for increased risk of biochemical failure, whereas the use of short-term neoadjuvant androgen deprivation therapy did not influence tumor-control outcomes even among intermediate-or high-risk patients. Seven-year incidence of distant metastases for low-, intermediate-, and high-risk patients were 5%, 3%, and 17%, respectively. Sevenyear incidence of late Grade 2 and 3 genitourinary toxicities were 22.1% and 4.9%, respectively and the 7-year incidence of Grade 2 and 3 gastrointestinal toxicities were 1% and 0.4%, respectively. CONCLUSION: HDR prostate brachytherapy in conjunction with supplemental EBRT results in excellent biochemical relapse-free survival rates with a low incidence of severe late genitourinary or gastrointestinal toxicities. The use of short-term neoadjuvant androgen deprivation did not influence long-term biochemical tumor control in this cohort. Ó
Introduction
In the radiotherapeutic management of clinically localized prostate cancer, dose escalation studies have been consistently associated with improved biochemical control outcomes and a reduction in distant metastases [DMs (1e5) ]. Furthermore, this favorable treatment response to higher radiation doses is most evident in patients with intermediate-and high-risk disease. Therefore, in an effort to escalate the intraprostatic dose without compromising periprostatic dose coverage, external beam radiation therapy (EBRT) has been used in combination with a high-doserate (HDR) brachytherapy boost. Recent evidence from our institution has demonstrated that the use of this combination treatment approach improves tumor control in those patients with intermediate-risk disease and selected patients with high-risk disease (6) .
In the present study, we report our long-term efficacy and toxicity outcomes using EBRT in combination with HDR brachytherapy for patients with clinically localized prostate cancer. Consistent with other reports (6e15), our data show that this combination treatment regimen is associated with excellent tumor control rates for favorable-and intermediate-risk patients and acceptably low rates of late genitourinary (GU) and gastrointestinal (GI) treatmentrelated toxicities.
Methods and materials
Between 1998 and 2010, 229 patients with clinically localized, biopsy-proven adenocarcinoma of the prostate were treated with HDR brachytherapy followed 3 weeks later by EBRT at Memorial Sloan-Kettering Cancer Center. The clinical characteristics of patients in this study are summarized in Table 1 . The patients were stratified into prognostic risk category groups based on the National Comprehensive Cancer Network classification system (www.nccn.com). This retrospective study was approved by the internal Institutional Review Board.
The HDR brachytherapy technique in use at our institution has been described previously (15) . In brief, the catheter placement is carried out under general anesthesia using a transperineal approach with a template-based technique using real-time transrectal ultrasound guidance. The clinical target volume (CTV) is defined as the prostate gland and the base of seminal vesicles, and the planning target volume is defined as a 3-mm margin around the CTV. Treatment planning for earlier cases in the series was performed using a software package developed at Memorial Sloan-Kettering Cancer Center with the following constraints relative to the prescription dose: 100% target coverage, 100e120% maximum urethra dose, and rectal maximum dose #100% of prescribed dose. Treatment planning for the latter part of the series was done using Brachyvision (Varian Medical Systems, Inc., Palo Alto, CA) with similar dose constraints. All patients in this series were treated with 192 Ir using Gam-maMed 12i or aGammaMed Plus remote afterloader (Varian). The first 45 patients were prescribed a peripheral dose of 550 cGy per fraction, the subsequent 40 patients received 600 cGy, the next 32 patients received 650 cGy, the next 108 patients received 700 cGy per fraction (the current dose in use at our institution), and 4 patients received 750 cGy per fraction. Each patient was treated with HDR brachytherapy delivered in three fractions at least 4 h apart. Patients were typically treated on the day of the implant and subsequent fractions were delivered on the following day with a minimum interfraction interval of 4 h to deliver the total dose within a 24-h time period.
Approximately 3 weeks after the HDR procedure, EBRT was initiated using conformal techniques described previously (15) . The CTV was defined for this phase of therapy as the prostate gland and seminal vesicles. The planning target volume was defined as a 1-cm margin around the CTV and a 3-mm margin at the prostate rectal interface. The first 11 patients received 4500 cGy in 25 fractions and 1 patient received 4860 cGy; all remaining patients (n 5 216) were prescribed 5040 cGy in 28 fractions. One patient was only able to undergo two fractions of brachytherapy (1400 cGy) as prescribed and underwent a course of EBRT to a total dose of 59.4 Gy. As of 2002, all patients were treated with intensity-modulated radiotherapy (IMRT) technique where a five-to seven-field treatment plan was used. EBRT was delivered to the prostate gland and seminal vesicles. The lymph nodes were not incorporated into the treatment fields.
For patients who received neoadjuvant androgen deprivation therapy (ADT; n 5 98; 42%), treatment was usually initiated 3 months before the three-dimensional conformal radiotherapy/IMRT and discontinued at the completion of radiotherapy. The ADT was given to patients with large prostates to achieve pretreatment volume reduction or to high-risk patients, and adjuvant ADT even for high-risk patients was not routinely given. The median duration of ADT used in these patients was 9 months (range, 1e33 months).
The median follow-up for the entire cohort of patients was 61.2 months (range, 3e150 months). Follow-up examinations consisted of an assessment of serum prostatespecific antigen (PSA), patient symptom assessment, and digital rectal examination. New or worsening acute and late GU and GI toxicities were scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events toxicity scale, version 3. Acute toxicity was defined as symptoms experienced by patients during the course of therapy and up to 90 days from the completion of EBRT. The International Prostate Symptom Score (IPSS) was used to assess urinary functioning (urinary frequency, hesitancy, urgency, intermittence, weak urinary stream, and nocturia) both before and after the treatment.
The patient's status was determined at the time of analysis in October 2011. The Phoenix definition of biochemical failure (absolute nadir plus 2 ng/mL with the corresponding date) was used for this analysis (16) . Actuarial likelihood of complication probabilities and disease-specific survival were calculated according to the product-limit estimate (Ka-planeMeier) method. The threshold of statistical significance for differences was set at 0.05.
Results

Tumor control and clinical outcomes
The 7-year PSA relapse-free survival rates were 95% (95% confidence interval [CI], 86.5e100.0%), 90% (95% CI, 84.4e96.9%), and 57% (95% CI, 38.2e80.8%) for low-, intermediate-, and high-risk patients, respectively (Fig. 1) . The median follow-up for each risk group was 69 months (range, 11e137 months), 64 months (range, 3e150 months), and 47 months (range, 5e140 months) for low-, intermediate-, and high-risk patients, respectively. In 206 patients who were free of biochemical relapse, 142 patients (69%) were noted to have PSA levels lower than 0.2 ng/mL at the time of last follow-up, and the PSA was undetectable (!0.05 ng/mL) at last follow-up in 85 (36%) of these patients.
The 7-year DMs-free survival for low-, intermediate-, and high-risk patients were 95%, 98%, and 83%, respectively. In the high-risk group among the 12 patients who developed a biochemical failure, 7 patients developed evidence of DMs at a median of 38 months after the treatment. At the time of last follow-up, 212 patients (93%) were alive. The incidence of prostate-specific mortality at 7 years for low-, intermediate-, and high-risk patients were 0%, 1.1% (95% CI, 0e3.1%), and 5.4% (95% CI, 0e16.1%), respectively.
The dose for the HDR boost ranged from 5.5 Gy Â 3 to 7.5 Gy Â 3 and were converted to biological equivalent doses (BEDs) as described in prior reports (17, 18) , and these BED levels ranged from 171 to 226 Gy with a median BED of 191.5 Gy. Although overall we did not appreciate any influence of BED on outcomes across all the patients, among high-risk patients there was apparent improved biochemical control and DMs-free survival outcomes among patients with BED values O190 Gy. Among patients with higher BED values (n 5 56), the incidence of PSA relapse and DMs at 7 years were 19% and 11% vs. 40% and 40%, respectively, among patients with lower BED values (n 5 5; p 5 0.03 for PSA outcomes and p 5 0.02 for DM outcomes).
GU toxicity
The frequency of GU toxicity is summarized in Table 2 . Thirty-five patients (15%) reported acute Grade 2 urinary toxicity (moderate urgency, frequency, dysuria, nocturia, or gross hematuria). Of these patients, 72% experienced symptom resolution at a median time of 7.3 months after therapy. Nine patients (4%) reported an acute urinary toxicity of Grade 3, manifesting as urinary retention, which resolved shortly with urinary catheterization. Seventy-five patients (33%) reported no acute urinary problems. The Pre-and posttreatment IPSS data were analyzed to evaluate GU toxicity levels in these patients in more detail. Pretreatment IPSS data was recorded for 173 patients and posttreatment IPSS data was recorded for 212 patients. The median pretreatment IPSS was 5 (range, 0e27) with 126 patients (73%) reporting mild symptoms (IPSS, 0e7), 42 patients (24%) with moderate symptoms (IPSS, 8e19), and 5 patients (3%) with severe urinary symptoms (IPSS, 20e35). For those patients with IPSS recorded at the last follow-up, the median posttreatment IPSS was 5e6 (range, 0e34) with 131 patients (62%) reporting mild symptoms, 65 patients (31%) with moderate symptoms, and 16 patients (7.5%) with severe urinary symptoms. A multivariate analysis, including age, the use of ADT, acute rectal toxicity, NCCN risk group, and baseline IPSS, did not reveal any variables predicting for increased risk of $Grade 2 late GU toxicity (see Table 3 ). Because urethral dose constraints were maintained in a tight range of 115e120% of the prescription dose, there was not a broad range of doses to analyze the influence of the urethral dose on toxicity in this cohort of patients.
GI toxicity
As shown in Table 4 , 69 patients (30%) experienced acute Grade 1 GI toxicity, mostly in the form of diarrhea and pelvic discomfort. These side effects resolved in 87% of patients at a median of 4 months after treatment. Only 2 patients (0.9%) reported a rectal toxicity of grade 2 (moderate diarrhea in both cases), which resolved in 1 patient and improved significantly in the second patient, shortly after treatment. No patients reported acute GI Grade 3 or 4 GI toxicity.
The 7-year incidence of Grade 2 and 3 late rectal toxicities were 1% and 0.4%, respectively. One patient (0.4%) reported Grade 3 GI toxicity (daily rectal bleeding requiring transfusion, which resolved after cauterization). Approximately 1 year after completing radiation therapy, 1 patient was found to have a midsigmoid stricture with fibrosis and angulation of the sigmoid distally on regular screening colonoscopy. The patient did not complain of abdominal pain and had regular bowel movements. The area of the stricture was laparoscopically resected and final pathology was consistent with diverticulitis and abscess formation. The location of the stricture was inside the treatment field of the EBRT, but outside of the high dose region of the brachytherapy treatment volume.
Discussion
In the management of patients with intermediate-and high-risk prostate adenocarcinoma, dose-escalation studies have demonstrated an improvement in tumor control, disease-free survival, and freedom from DMs (1e5, 19 ). Yet, the benefits of dose escalation must be weighed against the risks of toxicity to the surrounding normal tissue structures. For patients with disease localized to the prostate, HDR brachytherapy has been shown to be a favorable method of increasing the intraprostatic dose while minimizing the dose to peripheral sensitive structures. Our results indicate that a treatment regimen combining EBRT with a HDR brachytherapy boost is associated with a low likelihood of developing Grade 3 or higher GU or GI toxicities.
An interesting finding in our report was the observation of improved outcomes in the high-risk patient cohort when higher BED doses were delivered with the HDR. Among patients with BED doses O190 Gy (a/b ratio of 2), the 7year PSA relapse-free survival outcome for high-risk patients was 81% compared with 60% for patients who received lower dose levels ( p 5 0.02). In addition, dose escalation for this high-risk cohort was also associated with a reduction in improvement in the 7-year DMs-free survival outcomes from 60% to 89% for those who received lower and higher BED dose levels. These improved biochemical control outcomes for high-risk patients using higher doses appear to be consistent with what has been reported in Age in univariate analysis is significant, p 5 0.049. Table 5 ). Martinez et al. (20) had reported the outcomes of a cohort of 472 patients with intermediate-and high-risk disease treated with HDR brachytherapy and supplemental EBRT who were followed for a median of 8 years. The authors noted improved biochemical control and DMs-free survival outcomes with higher BED values. In that report, an a/b ratio of 1.2 was assumed and a 10-year PSA relapse rate of 19% and DMs incidence of 6% with BED values O268 was reported.
In our cohort of high-risk patients, it is also possible that longer courses of ADT and the use of elective nodal irradiation for this cohort could have further improved the tumor control outcomes. We recognize that in these patients a significant component of failure was DM. Patients developed metastases as confirmed by radionuclide bone scan and/or positron emission tomography imaging at a median of 38 months after treatment.
There are a several studies in addition to randomized controlled trials, which have reported outcomes and toxicity data for patients receiving HDR brachytherapy in addition to EBRT. A randomized phase III trial has demonstrated that HDR brachytherapy dose escalation resulted in a statistically significant reduction in the incidence of acute rectal toxicity and rectal discharge, which were considered surrogate markers for proctitis. Additionally, in patients with at least 2-year follow-up data available, there was no increase in late toxicities in patients receiving the HDR brachytherapy boost compared with the patients who received EBRT alone (21) . Another randomized trial with a median follow-up of 8.2 years demonstrated that the addition of a HDR brachytherapy boost was superior to EBRT alone for patients with locally advanced-staged prostate cancer. In that report, 29% of the patients in the HDR combined modality arm developed a biochemical failure compared with 61% in the EBRT arm ( p 5 0.024). In addition, the incidence of a positive posttreatment biopsy (2 years after treatment) in the HDR arm was significantly lower compared with the EBRT arm (24% vs. 51%; p 5 0.015) (22) . In a retrospective comparison from our institution, we also demonstrated that HDR brachytherapy combined with EBRT, especially for intermediate-risk patients, was associated with superior biochemical control outcomes compared with outcomes in a cohort of patients treated with high-dose IMRT (6) . An additional advantage of combined brachytherapy and EBRT dose escalation regimens for intermediate-and high-risk patients may be the opportunity, in selected cases, to avoid ADT, which has not been shown to be associated with improved outcomes (23, 24) .
We recognize the limitations of this study owing to it being a retrospective analysis, which reported on relatively small number of patients. It is also difficult to make any definitive conclusions regarding the BED dose advantage we observed in this study given the small number of patients comprising lower BED dose levels. Nevertheless, excellent biochemical control rates for patients with favorable-and intermediate-risk patients were achieved with this modality. An additional limitation of this study is that patients with high-risk disease were generally treated with short courses (#6e8 months) of ADT and it is possible that the use of longer courses of ADT could have further improved outcomes for this cohort.
Conclusion
HDR brachytherapy in combination with EBRT provides a high dose of irradiation to the prostate and is associated with excellent tumor-control rates. Higher BED doses were particularly important for improved local tumor control and reduced incidence of DMs for high-risk patients. We did not observe improved outcomes for patients treated with short-course ADT in conjunction with this combined-modality regimen, yet further studies will be required to determine if longer courses of adjuvant ADT would further improve outcomes in particular for highrisk prostate cancer patients. 
